VEN-120, a recombinant human lactoferrin, promotes a regulatory T cell [treg] phenotype and drives resolution of inflammation in distinct murine models of inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 11, Issue 9, 2017, Pages 1101-1112

  MacManus, Christopher F ^a   Collins, Colm B ^b   Nguyen, Tom T ^b   Alfano, Randall W ^a   Jedlicka, Paul ^c   de Zoeten, Edwin F ^b  

^a Ventria Bioscience   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Colitis; Lactoferrin; Regulatory T cells; VEN 120

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXTRAN SULFATE; IMMUNOMODULATING AGENT; LACTOFERRIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VEN 120; LTF PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; FLOW CYTOMETRY; HISTOLOGY; ILEITIS; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; LAMINA PROPRIA; LYMPHOCYTE SUBPOPULATION; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH17 CELL; TREG GENE; UPREGULATION; ANIMAL; C57BL MOUSE; HUMAN; IMMUNOLOGY; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; COLITIS; FLOW CYTOMETRY; HUMANS; ILEITIS; INFLAMMATORY BOWEL DISEASES; LACTOFERRIN; MICE; MICE, INBRED C57BL; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 85031325878     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjx056     Document Type: Article

References (81)

1. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140:1704-12
2. Dessein R, Chamaillard M, Danese S. Innate immunity in Crohn's disease: the reverse side of the medal. J Clin Gastroenterol 2008;42[Suppl 3 Pt 1]:S144-7
3. Stefanelli T, Malesci A, Repici A, Vetrano S, Danese S. New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets. Curr Drug Targets 2008;9:413-8
4. Naser SA, Romero C, Urbina P, Naser N, Valentine J. Cellular infiltration and cytokine expression correlate with fistulizing state in Crohn's disease. Clin Vaccine Immunol 2011;18:1416-9
5. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 1997;40:443-8
6. Funderburg NT, Stubblefield Park SR, Sung HC, et al. Circulating CD4[+] and CD8[+] T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology 2013;140:87-97
7. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009;15:199-207
8. Brock JH. The physiology of lactoferrin. Biochem Cell Biol 2002;80:1-6
9. Laibe S, Bard E, Biichlé S, et al. New sensitive method for the measurement of lysozyme and lactoferrin to explore mucosal innate immunity. Part II: time-resolved immunofluorometric assay used in HIV patients with oral candidiasis. Clin Chem Lab Med 2003;41:134-8
10. Ohashi Y, Ishida R, Kojima T, et al. Abnormal protein profiles in tears with dry eye syndrome. Am J Ophthalmol 2003;136:291-9
11. Niemelä A, Kulomaa M, Vija P, Tuohimaa P, Saarikoski S. Lactoferrin in human amniotic fluid. Hum Reprod 1989;4:99-101
12. Lin AL, Johnson DA, Patterson TF, et al. Salivary anticandidal activity and saliva composition in an HIV-infected cohort. Oral Microbiol Immunol 2001;16:270-8
13. Caccavo D, Sebastiani GD, Di Monaco C, et al. Increased levels of lactoferrin in synovial fluid but not in serum from patients with rheumatoid arthritis. Int J Clin Lab Res 1999;29:30-5
14. Zhang P, Sawicki V, Lewis A, Hanson L, Nuijens JH, Neville MC. Human lactoferrin in the milk of transgenic mice increases intestinal growth in ten-day-old suckling neonates. Adv Exp Med Biol 2001;501:107-13
15. Barboza M, Pinzon J, Wickramasinghe S, et al. Glycosylation of human milk lactoferrin exhibits dynamic changes during early lactation enhancing its role in pathogenic bacteria-host interactions. Mol Cell Proteomics 2012;11:M111.015248
16. Ochoa TJ, Cleary TG. Effect of lactoferrin on enteric pathogens. Biochimie 2009;91:30-4
17. Ammendolia MG, Agamennone M, Pietrantoni A, et al. Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus. Pathog Glob Health 2012;106:12-9
18. Mueller EA, Trapp S, Frentzel A, Kirch W, Brantl V. Efficacy and tolerability of oral lactoferrin supplementation in mild to moderate acne vulgaris: an exploratory study. Curr Med Res Opin 2011;27:793-7
19. Zavaleta N, Figueroa D, Rivera J, Sánchez J, Alfaro S, Lönnerdal B. Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea. J Pediatr Gastroenterol Nutr 2007;44:258-64
20. Lyons TE, Miller MS, Serena T, et al. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase clinical study. Am J Surg 2007;193:49-54
21. King JC Jr, Cummings GE, Guo N, et al. A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. J Pediatr Gastroenterol Nutr 2007;44:245-51
22. Ochoa TJ, Chea-Woo E, Campos M, et al. Impact of lactoferrin supplementation on growth and prevalence of Giardia colonization in children. Clin Infect Dis 2008;46:1881-3
23. Håversen LA, Baltzer L, Dolphin G, Hanson LA, Mattsby-Baltzer I. Antiinflammatory activities of human lactoferrin in acute dextran sulphateinduced colitis in mice. Scand J Immunol 2003;57:2-10
24. Togawa J, Nagase H, Tanaka K, et al. Oral administration of lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. J Gastroenterol Hepatol 2002;17:1291-8
25. Togawa J, Nagase H, Tanaka K, et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol 2002;283:G187-95
26. Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001;121:1428-36
27. Su L, Nalle SC, Shen L, et al. TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis. Gastroenterology 2013;145:407-15
28. Tao R, de Zoeten EF, Ozkaynak E, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007;13:1299-307
29. Zhang HL, Zheng YJ, Pan YD, et al. Regulatory T-cell depletion in the gut caused by integrin β7 deficiency exacerbates DSS colitis by evoking aberrant innate immunity. Mucosal Immunol 2016;9:391-400
30. Mori K, Yamanishi H, Ikeda Y, et al. Oral administration of carbonic anhydrase I ameliorates murine experimental colitis induced by Foxp3-CD4+CD25-T cells. J Leukoc Biol 2013;93:963-72
31. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/offregulation of TNF biosynthesis in mice lacking TNF AUrichelements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-98
32. Nguyen GC, Chong CA, Chong RY. National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis 2014;8:288-95
33. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17
34. Fazio VW, Wu JS. Surgical therapy for Crohn's disease of the colon and rectum. Surg Clin North Am 1997;77:197-210
35. Achkar JP, Shen B. Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence. Curr Gastroenterol Rep 2001;3:484-90
36. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008;135:1114-22
37. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010;97:404-9
38. Graham L. AGA reviews the use of corticosteroids, immunomodulators, and infliximab in IBD. Am Fam Physician 2007;75:4106
39. Baert FJ, D'Haens GR, Peeters M, et al. Tumor necrosis factor alpha antibody [infliximab] therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8
40. Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P. Management of ulcerative colitis and Crohn's disease. Acta Clin Belg 2004;59:304-14
41. Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol 2014;109:705-14
42. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35
43. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody [adalimumab] in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33; quiz 591
44. Sandborn WJ, Feagan BG, Stoinov S, et al.; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
45. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010;4:355-66
46. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98
47. Reddy JG, Loftus EV Jr. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006;35:837-55
48. Velusamy SK, Fine DH, Velliyagounder K. Prophylactic effect of human lactoferrin against Streptococcus mutans bacteremia in lactoferrin knockout mice. Microbes Infect 2014;16:762-7
49. Kimber I, Cumberbatch M, Dearman RJ, Headon DR, Bhushan M, Griffiths CE. Lactoferrin: influences on Langerhans cells, epidermal cytokines, and cutaneous inflammation. Biochem Cell Biol 2002;80:103-7
50. Hayashida K, Kaneko T, Takeuchi T, Shimizu H, Ando K, Harada E. Oral administration of lactoferrin inhibits inflammation and nociception in rat adjuvant-induced arthritis. J Vet Med Sci 2004;66:149-54
51. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumour necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol 1993;74:433-9
52. Pandiyan P, Zhu J. Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells. Cytokine 2015;76:13-24
53. Akin IM, Atasay B, Dogu F, et al. Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. Am J Perinatol 2014;31:1111-20
54. Yen CC, Lin CY, Chong KY, et al. Lactoferrin as a natural regimen for selective decontamination of the digestive tract: recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonates from pathogenic challenge in the gastrointestinal tract. J Infect Dis 2009;199:590-8
55. Hadis U, Wahl B, Schulz O, et al. Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. Immunity 2011;34:237-46
56. Hu S, Chen M, Wang Y, et al. mTOR inhibition attenuates dextran sulfate sodium-induced colitis by suppressing T cell proliferation and balancing TH1/TH17/Treg profile. PLoS One 2016;11:e0154564
57. Jhunjhunwala S, Chen LC, Nichols EE, Thomson AW, Raimondi G, Little SR. All-trans retinoic acid and rapamycin synergize with transforming growth factor-β1 to induce regulatory T cells but confer different migratory capacities. J Leukoc Biol 2013;94:981-9
58. Collins CB, Aherne CM, Kominsky D, et al. Retinoic acid attenuates ileitis by restoring the balance between T-helper 17 and T regulatory cells. Gastroenterology 2011;141:1821-31
59. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061-70
60. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117:3921-8
61. Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015;7:315ra189
62. Laffan AM, McKenzie R, Forti J, et al. Lactoferrin for the prevention of post-antibiotic diarrhoea. J Health Popul Nutr 2011;29:547-51
63. Brines RD, Brock JH. The effect of trypsin and chymotrypsin on the in vitro antimicrobial and iron-binding properties of lactoferrin in human milk and bovine colostrum. Unusual resistance of human apolactoferrin to proteolytic digestion. Biochim Biophys Acta 1983;759:229-35
64. Inubushi T, Kawazoe A, Miyauchi M, et al. Molecular mechanisms of the inhibitory effects of bovine lactoferrin on lipopolysaccharide-mediated osteoclastogenesis. J Biol Chem 2012;287:23527-36
65. Håversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 2002;220:83-95
66. Kim CW, Lee TH, Park KH, Choi SY, Kim J. Human lactoferrin suppresses TNF-α-induced intercellular adhesion molecule-1 expression via competition with NF-κB in endothelial cells. FEBS Lett 2012;586:229-34
67. Ando K, Hasegawa K, Shindo K, et al. Human lactoferrin activates NFkappaB through the Toll-like receptor 4 pathway while it interferes with the lipopolysaccharide-stimulated TLR4 signaling. FEBS J 2010;277:2051-66
68. Zong X, Song D, Wang T, et al. LFP-20, a porcine lactoferrin peptide, ameliorates LPS-induced inflammation via the MyD88/NF-κB and MyD88/MAPK signaling pathways. Dev Comp Immunol 2015;52:123-31
69. Willnow TE, Goldstein JL, Orth K, Brown MS, Herz J. Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. J Biol Chem 1992;267:26172-80
70. Jiang R, Lönnerdal B. Apo-and holo-lactoferrin stimulate proliferation of mouse crypt cells but through different cellular signaling pathways. Int J Biochem Cell Biol 2012;44:91-100
71. Takayama Y, Aoki R, Uchida R, Tajima A, Aoki-Yoshida A. Role of CXC chemokine receptor type 4 as a lactoferrin receptor. Biochem Cell Biol 2017;95:57-63
72. Stragier E, Van Assche G. The use of fecal calprotectin and lactoferrin in patients with IBD. Review. Acta Gastroenterol Belg 2013;76:322-8
73. Lamb CA, Mansfield JC. Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease. Frontline Gastroenterol 2011;2:13-8
74. Collins CB, Aherne CM, Ehrentraut SF, et al. Alpha-1-antitrypsin therapy ameliorates acute colitis and chronic murine ileitis. Inflamm Bowel Dis 2013;19:1964-73
75. Deboer MD. Use of ghrelin as a treatment for inflammatory bowel disease: mechanistic considerations. Int J Pept 2011;2011:189242
76. MacManus CF, Campbell EL, Keely S, Burgess A, Kominsky DJ, Colgan SP. Anti-inflammatory actions of adrenomedullin through fine tuning of HIF stabilization. FASEB J 2011;25:1856-64
77. Metelli A, Wu BX, Fugle CW, et al. Surface expression of TGFβ docking receptor GARP promotes oncogenesis and immune tolerance in breast cancer. Cancer Res 2016;76:7106-17
78. Seo YD, Pillarisetty VG. T-cell programming in pancreatic adenocarcinoma: a review. Cancer Gene Ther 2017;24:106-13
79. Domagala-Kulawik J, Osinska I, Hoser G. Mechanisms of immune response regulation in lung cancer. Transl Lung Cancer Res 2014;3:15-22
80. Ramalingam S, Crawford J, Chang A, et al.; FORTIS-M Study Investigators. Talactoferrin alfa versus placebo in patients with refractory advanced nonsmall-cell lung cancer [FORTIS-M trial]. Ann Oncol 2013;24:2875-80
81. Vincent JL, Marshall JC, Dellinger RP, et al.; Oral tAlactoferrin in Severe sepsIS Study Investigators. Talactoferrin in severe sepsis: results from the phase II/III Oral tAlactoferrin in severe sepsIS trial. Crit Care Med 2015;43:1832-8